Experiences with monoclonal antibody (mAb) administration for oncologic indications have led to the following safety and administration considerations.

**Preadministration**
- Complete a comprehensive patient assessment, including vascular access with the patency confirmed.
- Confirm the treatment with the patient. Verify consent. Reinforce patient education.
- Obtain any needed laboratory values or test results.
- With two professionals competent in the drug’s administration, review the orders and independently verify the medication and patient. Verify two patient identifiers, as well as drug name, dose, volume, and route and rate of administration.
- Verify that premedication, hydration, and other preparations are completed if prescribed.
- Prepare spill kit, and ensure that an emergency kit or other equipment is readily available.
- Prepare a primary line of a compatible carrier solution that can be started immediately after stopping the drug in the event of a reaction.

**Administration**
- mAbs are administered by IV infusion.
- With any new drug, safe handling precautions are recommended until a safety profile is determined. Nurses administering the drug should wear two pairs of chemotherapy-tested gloves when handling the medication in addition to the personal protective equipment used for infection control.
- Verify the patient using two identifiers.
- Verify the IV pump settings prior to beginning the infusion.
- Administer the drug as ordered.
- Monitor for acute side effects. (Some mAbs have protocols that call for frequent vital sign monitoring. Institutions should determine monitoring frequency and parameters based on reaction risk.)
- Document drug administration and patient response.
Infusion Reactions

Several types of infusion reactions can occur with mAbs. Hypersensitivity reactions are generally unexpected, regulated by the immune system, and allergic in nature. The reactions can be immediate (within five minutes) or delayed (hours to days after completion of the infusion). Anaphylactic reactions are hypersensitivity reactions that are systemic and can be life-threatening (Olsen et al., 2019; Roselló et al., 2017).

Prior to infusing a mAb, nurses should (Olsen et al., 2019):

- Verify patient allergies.
- Educate the patient about early signs of a reaction.
- Premedicate as prescribed.

Monitor patients closely for reactions, recognizing that the highest risk occurs during the first 5–15 minutes of the infusion. Vital sign changes are an early indication of a reaction.

Hypersensitivity Reactions

Consult the institution’s policies and procedures. As follows are some general guidelines.

- Stop the infusion of the suspected drug immediately, but maintain IV access.
- Call the healthcare provider, but stay with the patient. Do not leave.
- Assess the patient, and compare your evaluation to their baseline. Monitor the patient’s status closely.
- Provide emotional support.
- Prepare for and provide emergency treatment per orders or protocol.
- Administer histamine blockers as ordered.

Following resolution of symptoms, infusion may be ordered to resume at a slower rate (50%). The rate should be titrated slowly (Olsen et al., 2019).

Anaphylactic Reactions

Refer to accompanying STAT sheet

References
